GoodRx Holdings Forecast, price target & analysts
GoodRx Holdings Target price 2026 - Analyst rating & recommendation
GoodRx Holdings Classifications & Recommendation
GoodRx Holdings Price Target
| Target Price | $4.08 |
| Price | $3.28 |
| Potential |
24.39%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target GoodRx Holdings 2027 .
The average GoodRx Holdings target price is $4.08.
This is
24.39%
register free of charge
$5.25
60.06%
register free of charge
$2.68
18.40%
register free of charge
|
|
| A rating was issued by 21 analysts: 10 Analysts recommend GoodRx Holdings to buy, 9 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GoodRx Holdings stock has an average upside potential 2027 of
24.39%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 796.85 | 814.53 |
| 0.57% | 2.22% | |
| EBITDA Margin | 21.67% | 30.76% |
| 26.85% | 41.92% | |
| Net Margin | 3.82% | 12.97% |
| 84.67% | 239.53% |
17 Analysts have issued a sales forecast GoodRx Holdings 2026 . The average GoodRx Holdings sales estimate is
This results in the following potential growth metrics:
17 Analysts have issued an GoodRx Holdings EBITDA forecast 2026. The average GoodRx Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 GoodRx Holdings Analysts have issued a net profit forecast 2026. The average GoodRx Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.09 | 0.31 |
| 125.00% | 244.44% | |
| P/E | 10.56 | |
| EV/Sales | 1.61 |
16 Analysts have issued a GoodRx Holdings forecast for earnings per share. The average GoodRx Holdings EPS is
This results in the following potential growth metrics and future valuations:
GoodRx Holdings...
Current GoodRx Holdings Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Aug 21 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | May 14 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 21 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
May 14 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
May 11 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
